Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.37 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ACR | P10323 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | NEU3 | Q9UQ49 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10311696 | 1.00 | CYP2D6 (0.39) | CYP2D6CYP2C19ALDH1A1KMT2ACYP2C9 | |
| SCHEMBL10311725 | 1.00 | CYP2D6 (0.39) | CYP2D6CYP2C19ALDH1A1KMT2ACYP2C9 | |
| SCHEMBL17680117 | 0.84 | CYP2D6 (0.39) | CYP2D6CYP2C19ALDH1A1KMT2ACYP2C9 | |
| SCHEMBL13534167 | 0.84 | CYP2D6 (0.39) | CYP2D6CYP2C19ALDH1A1KMT2ACYP2C9 | |
| SCHEMBL1582718 | 0.84 | MEN1 (0.50) | CYP2D6CYP2C19ALDH1A1KMT2AMEN1 | |
| SCHEMBL21185864 | 0.84 | CYP2D6 (0.39) | CYP2D6CYP2C19ALDH1A1KMT2AMEN1 | |
| SCHEMBL3354440 | 0.81 | CYP2D6 (0.59) | CYP2D6CYP2C19ALDH1A1KMT2ACYP2C9 | |
| SCHEMBL20102958 | 0.80 | ANPEP (0.40) | CYP2D6CYP2C19ALDH1A1KMT2ACYP2C9 | |
| SCHEMBL7223053 | 0.80 | ANPEP (0.40) | CYP2D6CYP2C19ALDH1A1KMT2AMEN1 | |
| SCHEMBL1808926 | 0.80 | ANPEP (0.40) | CYP2D6CYP2C19ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117534834-A | Polymer, preparation method and application thereof, and intrinsic low-temperature curing negative photoresist | 上海交通大学 | 2024-02-09 | — | — | CN | claimed |
| WO-2024094645-A1 | NONSTICK POLYMER COATINGS FOR SHORT-TERM IMPLANTS | Universität Siegen (DE) | 2024-05-10 | — | — | WO | disclosed |
| CN-117534834-A | Polymer, preparation method and application thereof, and intrinsic low-temperature curing negative photoresist | 上海交通大学 | 2024-02-09 | — | — | CN | disclosed |
| WO-2023210671-A1 | COPOLYMER, POLYMER FILM, MEASURING DEVICE, AND SUPPORT FOR MEASUREMENT | 京セラ株式会社 | 2023-11-02 | — | — | WO | disclosed |
| US-11633486-B2 | Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease | THE UNIVERSITY OF CHICAGO (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220388964-A1 | (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | HIBERCELL, INC. | 2022-12-08 | — | — | US | disclosed |
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-09-30 | — | — | US | disclosed |
| US-11053216-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2021-07-06 | — | — | US | disclosed |
| US-20210069120-A1 | COMPOSITE NANOPARTICLE, PREPARATION METHOD THEREOF AND PREPARATION METHOD OF COMPOSITE NANO PREPARATION USING THEREOF | JINAN UNIVERSITY (CN) | 2021-03-11 | — | — | US | disclosed |
| US-20210000934-A1 | POLYMER ADJUVANT | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-01-07 | — | — | US | disclosed |
| US-20110118362-A1 | POLYMERS FOR CARDIOPULMONARY THERAPIES | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2011-05-19 | — | — | US | disclosed |
| US-20110085979-A1 | CONJUGATE OF A POLYMER, AN ANTI-ANGIOGENESIS AGENT AND A TARGETING MOIETY, AND USES THEREOF IN THE TREATMENT OF BONE RELATED ANGIOGENESIS CONDITIONS | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-04-14 | — | — | US | disclosed |
| US-20110086111-A1 | POLYMERIC SYSTEMS FOR THE DELIVERY OF ANTICANCER DRUGS | REXAHN PHARMACEUTICALS, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-7919076-B2 | PH-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy | ZENTIVA, K.S. (CZ) | 2011-04-05 | — | — | US | disclosed |
| WO-2010141330-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010045896-A2 | POLYMERIC COMPOSITION WITH SYNERGISTIC EFFECT IN TREATMENT OF TUMOUR DISEASES | ZENTIVA, K.S. (CZ) | 2010-04-29 | — | — | WO | disclosed |
| US-7691879-B2 | Isoquinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20090311182-A1 | Macromolecular Delivery Systems for Non-Invasive Imaging, Evaluation and Treatment of Arthritis and Other Inflammatory Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-12-17 | — | — | US | disclosed |
| EP-1782833-A2 | pH-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy | ZENTIVA, A.S. (CZ) | 2007-05-09 | — | — | EP | disclosed |
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210000934-A1 | POLYMER ADJUVANT | TLR3, TLR9, TLR1 | CYP2D6 4837/4885CYP2C19 4855/4885ALDH1A1 3788/4885 |
| US-20110086111-A1 | POLYMERIC SYSTEMS FOR THE DELIVERY OF ANTICANCER DRUGS | APEH, LNPEP, CPA3 | CYP2D6 2677/4885CYP2C19 2206/4885ALDH1A1 989/4885 |
| US-20110085979-A1 | CONJUGATE OF A POLYMER, AN ANTI-ANGIOGENESIS AGENT AND A TARGETING MOIETY, AND USES THEREOF IN THE TREATMENT OF BONE RELATED ANGIOGENESIS CONDITIONS | VEGFA, MVD, FLT1 | CYP2D6 4533/4885CYP2C19 4545/4885ALDH1A1 2529/4885 |
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | BRAF, RAF1, ARAF | CYP2D6 3584/4885CYP2C19 4116/4885ALDH1A1 1842/4885 |
| US-11633486-B2 | Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease | SI, FABP2, VIP | CYP2D6 2243/4885CYP2C19 1437/4885ALDH1A1 1366/4885 |
| US-20110118362-A1 | POLYMERS FOR CARDIOPULMONARY THERAPIES | TNNI3, TNNT2, TNNC1 | CYP2D6 3612/4885CYP2C19 2584/4885ALDH1A1 1799/4885 |
| US-11053216-B2 | Compounds and methods of use | TGFB2, TGFB1, HDGF | CYP2D6 4782/4885CYP2C19 4882/4885ALDH1A1 1992/4885 |
| US-20090311182-A1 | Macromolecular Delivery Systems for Non-Invasive Imaging, Evaluation and Treatment of Arthritis and Other Inflammatory Diseases | MMP1, MSR1, CD68 | CYP2D6 4618/4885CYP2C19 4862/4885ALDH1A1 4050/4885 |
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | CYP2D6 2475/4885CYP2C19 2784/4885ALDH1A1 2764/4885 |
| US-20220388964-A1 | (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | EIF2AK4, GCN1, GNAI2 | CYP2D6 908/4885CYP2C19 506/4885ALDH1A1 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.